Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation

This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor (EGFR) 19 exon deletion mutation treated with 500 mg/m(2) pemetrexed and 75 mg/m(2) cisplatin on day 1, sequenced with 250 mg gefitinib on prescription on days 4–28 for six cyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Aimi, Li, Rong, Zhao, Jikai, Wang, Xiaofei, Jin, Bo, Niu, Yanjie, Zhang, Jie, Jiang, Liyan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193016/
https://www.ncbi.nlm.nih.gov/pubmed/27766772
http://dx.doi.org/10.1111/1759-7714.12364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193016/
https://www.ncbi.nlm.nih.gov/pubmed/27766772
http://dx.doi.org/10.1111/1759-7714.12364

Ejemplares similares